BACKGROUND: Patients with schizophrenia show increased brain and cerebrospinal fluid (CSF) concentrations of the endogenous N-methyl-D-aspartate receptor antagonist kynurenic acid (KYNA). This compound is an end-metabolite of the kynurenine pathway, and its formation indirectly depends on the activity of kynurenine 3-monooxygenase (KMO), the enzyme converting kynurenine to 3-hydroxykynurenine. METHODS: We analyzed the association between KMO gene polymorphisms and CSF concentrations of KYNA in patients with schizophrenia and healthy controls. Fifteen single nucleotide polymorphisms (SNPs) were selected covering KMO and were analyzed in UNPHASED. RESULTS: We included 17 patients with schizophrenia and 33 controls in our study. We found an association between a KMO SNP (rs1053230), encoding an amino acid change of potential importance for substrate interaction, and CSF concentrations of KYNA. LIMITATIONS: Given the limited sample size, the results are tentative until replication. CONCLUSION: Our results suggest that the nonsynonymous KMO SNP rs1053230 influences CSF concentrations of KYNA.
BACKGROUND:Patients with schizophrenia show increased brain and cerebrospinal fluid (CSF) concentrations of the endogenous N-methyl-D-aspartate receptor antagonist kynurenic acid (KYNA). This compound is an end-metabolite of the kynurenine pathway, and its formation indirectly depends on the activity of kynurenine 3-monooxygenase (KMO), the enzyme converting kynurenine to 3-hydroxykynurenine. METHODS: We analyzed the association between KMO gene polymorphisms and CSF concentrations of KYNA in patients with schizophrenia and healthy controls. Fifteen single nucleotide polymorphisms (SNPs) were selected covering KMO and were analyzed in UNPHASED. RESULTS: We included 17 patients with schizophrenia and 33 controls in our study. We found an association between a KMO SNP (rs1053230), encoding an amino acid change of potential importance for substrate interaction, and CSF concentrations of KYNA. LIMITATIONS: Given the limited sample size, the results are tentative until replication. CONCLUSION: Our results suggest that the nonsynonymous KMO SNP rs1053230 influences CSF concentrations of KYNA.
Authors: Klas R Linderholm; Elisabeth Skogh; Sara K Olsson; Marja-Liisa Dahl; Maria Holtze; Göran Engberg; Martin Samuelsson; Sophie Erhardt Journal: Schizophr Bull Date: 2010-08-20 Impact factor: 9.306
Authors: L K Nilsson; K R Linderholm; G Engberg; L Paulson; K Blennow; L H Lindström; C Nordin; A Karanti; P Persson; S Erhardt Journal: Schizophr Res Date: 2005-08-25 Impact factor: 4.939
Authors: Marian L Hamshere; Phil Bennett; Nigel Williams; Ricardo Segurado; Alastair Cardno; Nadine Norton; David Lambert; Hywel Williams; George Kirov; Aiden Corvin; Peter Holmans; Lisa Jones; Ian Jones; Michael Gill; Michael C O'Donovan; Michael J Owen; Nick Craddock Journal: Arch Gen Psychiatry Date: 2005-10
Authors: Roy M Nilsen; Anne-Lise Bjørke-Monsen; Oivind Midttun; Ottar Nygård; Eva R Pedersen; Arve Ulvik; Per Magnus; Håkon K Gjessing; Stein Emil Vollset; Per Magne Ueland Journal: Obstet Gynecol Date: 2012-06 Impact factor: 7.661
Authors: Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero Journal: Schizophr Bull Date: 2017-07-01 Impact factor: 9.306
Authors: Maximilian Tufvesson-Alm; Lilly Schwieler; Robert Schwarcz; Michel Goiny; Sophie Erhardt; Göran Engberg Journal: Neuropharmacology Date: 2018-06-05 Impact factor: 5.250
Authors: Michelle L Pershing; David M Bortz; Ana Pocivavsek; Peter J Fredericks; Christinna V Jørgensen; Sarah A Vunck; Benedetta Leuner; Robert Schwarcz; John P Bruno Journal: Neuropharmacology Date: 2014-11-01 Impact factor: 5.250
Authors: Michelle L Pershing; David Phenis; Valentina Valentini; Ana Pocivavsek; Derick H Lindquist; Robert Schwarcz; John P Bruno Journal: Psychopharmacology (Berl) Date: 2016-08-16 Impact factor: 4.530
Authors: Joshua Chiappelli; Ana Pocivavsek; Katie L Nugent; Francesca M Notarangelo; Peter Kochunov; Laura M Rowland; Robert Schwarcz; L Elliot Hong Journal: JAMA Psychiatry Date: 2014-07-01 Impact factor: 21.596